Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.

被引：0
|
作者：
Karimi, Yasmin
Ghesquieres, Herve
Jurczak, Wojciech
Cheah, Chan
Clausen, Michael
Lugtenburg, Pieternella
Cunningham, David
Do, Young Rok
Lewis, David John
Gasiorowski, Robin
Kim, Tae Min
Van der Poel, Marjolein
Poon, Michelle Li Mei
Feldman, Tatyana A.
Linton, Kim M.
Sureda, Anna
Hutchings, Martin
Stirner, Mariana Cota
Sacchi, Mariana
Thieblemont, Catherine
机构：
[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA
[2] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France
[3] MSC Natl Res Inst Oncol, Krakow, Poland
[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[5] Vejle Hosp, Vejle, Denmark
[6] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
[7] Royal Marsden NHS Fdn Trust, Sutton, England
[8] Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea
[9] Univ Hosp Plymouth NHS Trust, Derriford Hosp, Plymouth, England
[10] Univ Sydney, Concord Hosp, Sydney, NSW, Australia
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Maastricht Univ, Med Ctr, Maastricht Dept Internal Med, Div Hematol GROW,Sch Oncol & Dev Biol, Maastricht, Netherlands
[13] Natl Univ Singapore Hosp, Singapore, Singapore
[14] Hackensack Univ, Hackensack Meridian Hlth, Med Ctr, Hackensack, NJ USA
[15] Christie NHS Fdn Trust, Manchester, England
[16] Manchester Canc Res Ctr, Manchester, England
[17] Univ Barcelona, Inst Catal Oncol, Hosp Duran & Reynals, IDIBELL,Hosp Llobregat, Barcelona, Spain
[18] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[19] AbbVie Inc, N Chicago, IL USA
[20] Genmab, Princeton, NJ USA
[21] Univ Paris, Hop St Louis, Assistance Publ & Hop Paris APHP, Hematooncol, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7525
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial
    Karimi, Yasmin
    Ghesquieres, Herve
    Jurczak, Wojciech
    Cheah, Chan Y.
    Clausen, Michael Roost
    Lugtenburg, Pieternella
    Cunningham, David
    Do, Young Rok
    Lewis, David John
    Gasiorowski, Robin
    Kim, Tae Min
    van der Poel, Marjolein
    Poon, Michelle Limei
    Feldman, Tatyana
    Linton, Kim M.
    Sureda, Anna
    Hutchings, Martin
    Stirner, Mariana Cota
    Liu, Yan
    Kilavuz, Nurgul
    Sacchi, Mariana
    Thieblemont, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S438 - S438
  • [2] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
    Catherine, Thieblemont
    Tycel, Phillips
    Herve, Ghesquieres
    Cheah, Chan Y.
    David, Cunningham
    Do, Young R.
    Tatyana, Feldman
    Robin, Gasiorowski Robin
    Wojciech, Jurczak
    Tae, Min Kim Tae M.
    Lewis, David J.
    Mariolein, Van der Poe
    Poon, Michelle L.
    Thomas, Doerr
    Nurgul, Kilavuz
    Menghui, Chen
    Mariana, Sacchi
    Martin, Hutchings
    Pieternella, Lugtenburg
    Roost, Clausen Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
  • [3] Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
    Thieblemont, Catherine
    Karimi, Yasmin H.
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Jurczak, Wojciech
    Do, Young Rok
    Gasiorowski, Robin
    Lewis, David John
    Kim, Tae Min
    van der Poel, Marjolein
    Poon, Michelle Limei
    Feldman, Tatyana
    Linton, Kim M.
    Sureda, Anna
    Hutchings, Martin
    Dinh, Minh H.
    Kilavuz, Nurgul
    Soong, David
    Mark, Thomas
    Sacchi, Mariana
    Phillips, Tycel
    Lugtenburg, Pieternella J.
    LEUKEMIA, 2024, : 2653 - 2662
  • [4] Subcutaneous Epcoritamab in Patients with Relapsed/ Refractory Large B-Cell Lymphoma: Longer-Term Results From the Pivotal EPCORE NHL-1 Trial
    Tatyana, Feldman
    Yasmin, Karimi
    Herve, Ghesquieres
    Wojciech, Jurczak
    Chan, Cheah Y.
    Michael, Roost Clausen
    Pieternella, Lugtenburg
    David, Cunningham
    Do Young, Rok
    John, Lewis David
    Robin, Gasiorowski
    Min, Kim Tae
    Marjolein, van der Poel
    Michelle, Limei Poon
    Kim, Linton M.
    Anna, Sureda
    Martin, Hutchings
    Mariana, Cota Stirner
    Mariana, Sacchi
    Catherine, Thieblemont
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S49 - S50
  • [5] Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
    Thieblemont, Catherine
    Phillips, Tycel
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Do, Young Rok
    Feldman, Tatyana
    Gasiorowski, Robin
    Jurczak, Wojciech
    Kim, Tae Min
    Lewis, David John
    van der Poel, Marjolein
    Poon, Michelle Limei
    Doerr, Thomas
    Kilavuz, Nurgul
    Chen, Menghui
    Sacchi, Mariana
    Elliott, Brian
    Hutchings, Martin
    Lugtenburg, Pieternella
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S379 - S379
  • [6] Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)
    Karimi, Yasmin
    Thieblemont, Catherine
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Jurczak, Wojciech
    Linton, Kim M.
    Hutchings, Martin
    Phillips, Tycel Jovelle
    Farooq, Umar
    Kim, Won Seog
    Dinh, Minh H.
    Ghosh, Jagannath
    Pallai, Rajash
    Wielgos-Bonvallet, Monica
    Eskelund, Christian
    Lugtenburg, Pieternella
    Vose, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Subcutaneous epcoritamab induces durable complete remissions in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: long-term results from the EPCORE NHL-1 Phase 2 expansion cohort
    Scholz, C. W.
    Karimi, Y.
    Ghesquieres, H.
    Jurczak, W.
    Cheah, C. Y.
    Clausen, M. R.
    Lugtenburg, P.
    Cunningham, D.
    Do, Y. R.
    Lewis, D. J.
    Gasiorowski, R.
    Kim, T. M.
    van der Poel, M.
    Poon, M. L.
    Feldman, T.
    Linton, K. M.
    Sureda, A.
    Hutchings, M.
    Stirner, Cota M.
    Liu, Y.
    Kilavuz, N.
    Sacchi, M.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 268 - 269
  • [8] Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)
    Phillips, Tycel
    Lugtenburg, Pieternella
    Kalsekar, Anupama
    Mutebi, Alex
    Wang, Anthony
    Blaedel, Julie
    Kosa, Katherine
    Martin, Susan
    Sacchi, Mariana
    Thieblemont, Catherine
    BLOOD, 2022, 140 : 8022 - 8023
  • [9] Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
    Izutsu, Koji
    Kumode, Takahiro
    Yuda, Junichiro
    Nagai, Hirokazu
    Mishima, Yuko
    Suehiro, Youko
    Yamamoto, Kazuhito
    Fujisaki, Tomoaki
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Ikezoe, Takayuki
    Nishikori, Momoko
    Akahane, Daigo
    Fujita, Jiro
    Wu, Jun
    Broberg, Per
    Buchbjerg, Jeppe
    Fukuhara, Noriko
    ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1389
  • [10] Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5
    Mazza, Irit Avivi
    Kim, Won Seog
    Ko, Shen
    Grande, Carlos
    Lavie, David
    Chism, David
    Seliem, Mostafa
    Jeng, Edwin E.
    Joshi, Neha
    Siddani, Satya
    Assaily, Wissam
    Sacchi, Mariana
    Dinh, Minh
    Avigdor, Abraham
    BLOOD, 2023, 142
12345